USPTO issues patent number to Vermillion's biomarkers for detecting ovarian cancer

Vermillion, Inc. (OTC: VRMLQ.PK), a molecular diagnostics company, today announced that the U.S. Patent Office (USPTO) has issued patent number 7,605,003 titled "Use of biomarkers for detecting ovarian cancer" to the Company for the discovery of biomarkers for ovarian cancer. The patent covers biomarker combinations for both the diagnosis and management of ovarian cancer and covers measurement of the markers by a variety of methods, including mass spectrometry and immunoassay approaches.

"Vermillion has been creating a comprehensive patent portfolio to protect our ovarian cancer testing franchise. The issuance of this patent supports our overall intellectual property strategy and we continue to pursue additional patent applications in support of our diagnostic programs," said Gail S. Page, Vermillion Executive Chairperson.


Vermillion, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Four-drug chemotherapy regimen provides longer overall survival for metastatic pancreatic ductal adenocarcinoma